SJF 1521 is a selective EGFR PROTAC™ Degrader. SJF 1521 comprises the EGFR inhibitor lapatinib (Cat. No. 6811) joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Exhibits selectivity for EGFR, including mutant forms, over HER2. Induces degradation of EGFR in OVCAR8 cells. PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
- Nom chimique ou matériau
- (2 S,4 R)-1-(-2-(tert-Butyl)-14-(4-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)phenoxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
- CAS
- 2230821-40-4
- Quantité
- 5 mg
- Cible
- Active Degraders
- Formule moléculaire
- C57H61ClFN7O9S
- Pureté
- 0.98
